Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Filings indexed 686 across all filing types
Latest filing 2022-08-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
祥生医疗2022年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Half-Year Special Report on the Deposit and Use of Raised Funds" by Wuxi Xiangsheng Medical Technology Co., Ltd. It details the amount of funds raised, their deposit, usage, management, and investment of idle funds. The content focuses on the company's fundraising activities, the management of those funds, and their specific usage during the half-year period ending June 30, 2022. There are no full financial statements or comprehensive financial performance data typical of an interim or annual report. Instead, it is a specialized report on the use of capital raised through an IPO and subsequent management of those funds. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7812 characters) is sufficient to be a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2022-08-19 Chinese
祥生医疗关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders (临时股东大会) for Wuxi Xiangsheng Medical Technology Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and includes an authorization letter for proxy voting. There is no financial data, earnings, or audit information presented. The document is an announcement informing shareholders about the meeting and how to participate, rather than the meeting materials or results themselves. The document length is 2875 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including notices of meetings.
2022-08-19 Chinese
上海荣正投资咨询股份有限公司关于无锡祥生医疗科技股份有限公司2021年限制性股票激励计划首次授予部分第一个归属期归属条件成就之独立财务顾问报告
Regulatory Filings
2022-08-19 Chinese
祥生医疗关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations for Wuxi Xiangsheng Medical Technology Co., Ltd. It details the stock price movements over specific dates, the company's self-inspection results, confirmation from controlling shareholders, and risk warnings to investors. It references regulatory rules from the Shanghai Stock Exchange and includes a statement from the board. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure about stock trading anomalies. It is not an annual or interim report, earnings release, or any other financial report type. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2022-07-25 Chinese
控股股东、实际控制人关于祥生医疗股票交易异常波动问询函的回函
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for omitted pictures and no substantive textual content or financial data. The length is very short (266 characters) and does not contain any report, announcement, or detailed information. It does not meet criteria for any specific report or announcement category. Given the lack of content, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous or non-classifiable filings.
2022-07-25 Chinese
祥生医疗2022年半年度业绩预告的自愿性披露公告
Earnings Release Classification · 95% confidence The document is a voluntary disclosure announcement of the company's 2022 half-year performance forecast, including estimated net profit and profit excluding non-recurring items for the period January 1 to June 30, 2022. It explicitly states that the data is preliminary, unaudited, and that the official half-year report will be published later. The document is short (1519 characters) and does not contain actual financial statements or detailed financial analysis, only forecasted figures and explanations. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, rather than a full Interim/Quarterly Report (IR) which would contain substantive financial data. Therefore, the correct classification is Earnings Release (ER). H1 2022
2022-07-20 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.